RVNC stock forecast
Our latest prediction for Revance Therapeutics Inc's stock price was made on the March 6, 2023 when the stock price was at 32.99$.
In the short term (2weeks), RVNC's stock price should underperform the market by -2.08%. During that period the price should oscillate between -9.18% and +6.29%.
In the medium term (3months), RVNC's stock price should underperform the market by -14.22%. During that period the price should oscillate between -26.17% and +15.23%.
Get email alertsCreate a solid portfolio with RVNC
About Revance Therapeutics Inc
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.90$ per share.
The book value per share is 5.68$
Three months stock forecastMarch 6, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 312.35% | -341M | -384222.47% | -356M | -4.90 | - | - | 82M | 5.68 | - | - | - |